Peer Review reports
From: Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases
| Original Submission | ||
|---|---|---|
| 29 Oct 2018 | Submitted | Original manuscript |
| 23 Jan 2019 | Reviewed | Reviewer Report - Yanmin Zhu |
| 31 Jan 2019 | Reviewed | Reviewer Report - Eric Finkelstein |
| 7 Mar 2019 | Author responded | Author comments - Savio Sodre |
| Resubmission - Version 2 | ||
| 7 Mar 2019 | Submitted | Manuscript version 2 |
| 29 Mar 2019 | Reviewed | Reviewer Report - Yanmin Zhu |
| 29 Mar 2019 | Reviewed | Reviewer Report - Eric Finkelstein |
| 5 Jul 2019 | Author responded | Author comments - Savio Sodre |
| Resubmission - Version 3 | ||
| 5 Jul 2019 | Submitted | Manuscript version 3 |
| 24 Jul 2019 | Reviewed | Reviewer Report - Eric Finkelstein |
| 8 Aug 2019 | Author responded | Author comments - Savio Sodre |
| Resubmission - Version 4 | ||
| 8 Aug 2019 | Submitted | Manuscript version 4 |
| 10 Aug 2019 | Reviewed | Reviewer Report - Eric Finkelstein |
| 26 Aug 2019 | Author responded | Author comments - Savio Sodre |
| Resubmission - Version 5 | ||
| 26 Aug 2019 | Submitted | Manuscript version 5 |
| Publishing | ||
| 28 Aug 2019 | Editorially accepted | |
| 11 Sep 2019 | Article published | 10.1186/s12889-019-7562-y |
You can find further information about peer review here.